This MedLibrary.org supplementary page on Imidazoline receptor is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
| Imidazoline | |
|---|---|
 |
|
| IUPAC name | 4,5-dihydro-1H-imidazole |
| Identifiers | |
| CAS number | [504-75-6] |
| SMILES |
|
| Properties | |
| Molecular formula | C3H6N2 |
| Molar mass | 70.093 g/mol |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox disclaimer and references |
|
Imidazoline is a nitrogen-containing heterocycle derived from imidazole. The ring contains an imine bond, and the carbons at the 4 and 5 positions are singly bonded, rather than doubly bonded for the case of imidazole. Imidazolines are structurally related to guanidines and amidines.
Like imidazole, imidazoline-based compounds have been used as N-heterocyclic carbene ligands on various transition metals. It is found in the commercially available second generation Grubbs' catalyst.
Biological role
Many imidazolines are biologically active.[1] Most bio-active derivatives bear a substituent (aryl or alkyl group) on the carbon between the nitrogen centers. Some brand names include oxymetazoline, xylometazoline, tetrahydrozoline, and naphazoline.
Receptor
There are several receptors of imidazoline, most notably the I1-imidazoline receptor. The I1-imidazoline receptor results in hydrolysis of phosphatidylcholine. This generates DAG, arachidonic acid and eicosanoids [2]. In addition, the sodium-hydrogen antiporter is inhibited, and enzymes of catecholamine synthesis is induced. The I1-imidazoline receptor may belong to the neurocytokine receptor family, since its signaling pathways are similar to those of interleukins.[2]
Agonists include the antihypertensive moxonidine, while antagonists include idazoxan.
References
- ^ N. MacInnes and S. Duty (2004). "Locomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway". Br J Pharmacol 143 (8): 952–959. doi:.
- ^ a b The I1-Imidazoline Receptor and Its Cellular Signaling Pathways PAUL ERNSBERGER, Departments of Nutrition, Medicine, Pharmacology, and Neuroscience, Case Western Reserve School of Medicine, Cleveland, Ohio 44106-4906, USA
 |
This article about a heterocyclic compound is a stub. You can help Wikipedia by expanding it. |
Wikipedia content modification information:
- This page was last modified on 18 June 2008, at 09:19.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Imidazoline receptor".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.